Effect of Granulocyte Colony-Stimulating Factor in Patients with Diffuse Large Cell Lymphoma Treated with Intensive Chemotherapy
- 1 January 1994
- journal article
- clinical trial
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 15 (1-2) , 153-157
- https://doi.org/10.3109/10428199409051691
Abstract
We investigated whether Granulocyte colony-stimulating factor (G-CSF) could prevent myelotoxicity or accelerate hematopoietic recovery after intensive chemotherapy in previously untreated patients with diffuse large cell lymphoma (DLCL). Forty-two patients were included in a prospective clinical trial in which alternating chemotherapy ESAP (etoposide, Solu-Medrol, cytosine arabinoside, cis-platinum), m-BECOD (low doses methotrexate, bleomycin, epirubicin, cyclophosphamide, vincristine, dexamethasone), MVPP-Bleo (mitoxantrone, vincristine, prednisone, procarbazine, bleomycin) were administered by 9 cycles. Each cycle was followed by 10 days of G-CSF (5 ug/kg/day) started five days after chemotherapy compared to a control group which received chemotherapy without G-CSF support. Leucocytes and granulocytes were significantly higher in patients receiving G-CSF compared to the control group. The total number of days of leukopenia (WBC counts below 2.0 × 109/L and absolute granulocytes below 1.0 × 109/L) were longer in the patients without G-CSF compared to those who received G-CSF (14.1 days versus 1.9 days). Delays in treatment were most frequent in the control group: 38% versus 4% in all cycles. Infection episodes occurred in 41 out of 168 cycles (25%) in the control group compared to 7 out of 172 (4%) in the G-CSF arm. Complete response was achieved in 12 out of 22 (54%) in the control group compared to 16 out 20 (80%) in the patients who received G-CSF. Toxicity secondary to G-CSF was mild. G-CSF can be administered safely to patients with DLCL and results in improved hematologic recovery after intensive chemotherapy. Full dose chemotherapy can be administered on time, resulting in an increase in the overall response and less infectious complications when compared to the control group. We feel that G-CSF should be introduced in clinical trials with more intensive chemotherapy for patients with DLCL in order to improve the type and probable duration of response.Keywords
This publication has 15 references indexed in Scilit:
- Treatment of Non-Hodgkin's LymphomaNew England Journal of Medicine, 1993
- Effects of hematopoietic growth factors on chemotherapy-induced myelosuppressionCritical Reviews in Oncology/Hematology, 1992
- Effect of recombinant human granulocyte-macrophage colony-stimulating factor in patients with Hodgkin's disease: a phase I/II study.Journal of Clinical Oncology, 1992
- The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1991
- Effect of granulocyte colony-stimulating factor on neutropenia due to chemotherapy for non-Hodgkin's lymphomaCancer, 1990
- Survival of diffuse large cell lymphoma. A multivariate analysis including dose intensity variablesCancer, 1990
- Treatment of chemotherapy-induced neutropenia by subcutaneously administered granulocyte colony-stimulating factor with optimization of dose and duration of therapy.Journal of Clinical Oncology, 1989
- The use of granulocyte colony-stimulating factor to increase the intensity of treatment with doxorubicin in patients with advanced breast and ovarian cancerBritish Journal of Cancer, 1989
- Effect of Granulocyte Colony-Stimulating Factor on Neutropenia and Associated Morbidity Due to Chemotherapy for Transitional-Cell Carcinoma of the UrotheliumNew England Journal of Medicine, 1988
- EFFECT OF GRANULOCYTE COLONY STIMULATING FACTOR ON NEUTROPENIA INDUCED BY CYTOTOXIC CHEMOTHERAPYThe Lancet, 1988